News

Top line results from the study announced last month revealed the treatment missed its primary endpoint. Howevr, additional data analysis showed that in the European cohort, Lupuzor had a statistically significant 71.1% response rate against

The study is a combined Phase I and II study in approximately 40 patients to be conducted at specialist centres at the University of California, San Francisco and

The phase I MMY2036 study of daratumumab plus JNJ-63723283, an anti PD-1 antibody in patients with multiple myeloma, will also be terminated. The Data Monitoring Committee (DMC) has

The agreement outlines the legal terms under which Beactica and Sanofi collaborate on the characterization of interactions between novel therapeutics and their target proteins. As part of the

The phase III pacific trial is a randomized, double-blinded, placebo-controlled, multi-center trial of Imfinzi in patients with unresectable Stage III NSCLC whose disease has not progressed following platinum-based chemotherapy concurrent with

Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult Crohn's disease, pediatric Crohn's disease, adult ulcerative colitis, pediatric ulcerative colitis, ankylosing spondylitis,

Built on the heritage of the market-leading Zetasizer Nano range, and already the proud recipients of a Red Dot 2018 design award, these new flagship instruments deliver significant

According to the drug regulator, patients with PKU suffer from an inability to break down phenylalanine (Phe) since their birth. Palynziq has been developed to reduce blood phenylalanine

The CRL is consistent with the preliminary feedback Cosmo announced on May 9, 2018, stating that the FDA identified unspecified deficiencies that preclude the continuation of the discussion